CUEDC2

Summary

CUEDC2 (CUE domain containing 2, HGNC:28352) is a protein-coding gene on chromosome 10q24.32, encoding CUE domain-containing protein 2 (Q9H467). Down-regulates ESR1 protein levels through the ubiquitination-proteasome pathway, regardless of the presence of 17 beta-estradiol.

Predicted to enable ubiquitin binding activity. Acts upstream of or within negative regulation of cytokine production involved in inflammatory response and negative regulation of macrophage cytokine production. Located in cytosol; nuclear membrane; and nucleoplasm.

Source: NCBI Gene 79004 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 54 total
• MANE Select transcript: NM_024040

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28352
Approved symbol	CUEDC2
Name	CUE domain containing 2
Location	10q24.32
Locus type	gene with protein product
Status	Approved
Aliases	MGC2491
Ensembl gene	ENSG00000107874
Ensembl biotype	protein_coding
OMIM	614142
Entrez	79004

Gene structure

Transcript identifiers

Ensembl transcripts: 24 — 21 protein_coding, 3 protein_coding_CDS_not_defined

ENST00000369937, ENST00000465409, ENST00000477994, ENST00000486762, ENST00000888778, ENST00000888779, ENST00000888780, ENST00000888781, ENST00000888782, ENST00000888783, ENST00000888784, ENST00000888785, ENST00000925786, ENST00000925787, ENST00000925788, ENST00000925789, ENST00000925790, ENST00000925791, ENST00000925792, ENST00000925793, ENST00000925794, ENST00000941431, ENST00000941432, ENST00000941433

RefSeq mRNA: 1 — MANE Select: NM_024040 NM_024040

CCDS: CCDS41566

Canonical transcript exons

ENST00000369937 — 9 exons

Exon	Start	End
ENSE00000722774	102423798	102423859
ENSE00000722775	102423996	102424178
ENSE00001451309	102432526	102432574
ENSE00003551863	102424499	102424560
ENSE00003552624	102424264	102424394
ENSE00003594851	102423657	102423717
ENSE00003650852	102425115	102425198
ENSE00003660236	102424649	102424792
ENSE00003674284	102423249	102423572

Expression profiles

Bgee: expression breadth ubiquitous, 281 present calls, max score 97.67.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 24.6983 / max 177.0334, expressed in 1817 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
111169	19.7138	1814
111170	4.9845	1601

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
olfactory bulb	UBERON:0002264	97.67	gold quality
apex of heart	UBERON:0002098	97.35	gold quality
tibial nerve	UBERON:0001323	97.26	gold quality
ganglionic eminence	UBERON:0004023	97.15	gold quality
prefrontal cortex	UBERON:0000451	97.14	gold quality
right frontal lobe	UBERON:0002810	97.14	gold quality
anterior cingulate cortex	UBERON:0009835	96.95	gold quality
cingulate cortex	UBERON:0003027	96.94	gold quality
right adrenal gland	UBERON:0001233	96.71	gold quality
right adrenal gland cortex	UBERON:0035827	96.71	gold quality
heart left ventricle	UBERON:0002084	96.63	gold quality
right atrium auricular region	UBERON:0006631	96.63	gold quality
cardiac ventricle	UBERON:0002082	96.53	gold quality
left adrenal gland cortex	UBERON:0035825	96.51	gold quality
gastrocnemius	UBERON:0001388	96.50	gold quality
left adrenal gland	UBERON:0001234	96.47	gold quality
amygdala	UBERON:0001876	96.45	gold quality
lower esophagus muscularis layer	UBERON:0035833	96.39	gold quality
Brodmann (1909) area 9	UBERON:0013540	96.38	gold quality
lower esophagus	UBERON:0013473	96.36	gold quality
caudate nucleus	UBERON:0001873	96.29	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	96.29	gold quality
muscle of leg	UBERON:0001383	96.28	gold quality
nucleus accumbens	UBERON:0001882	96.23	gold quality
putamen	UBERON:0001874	96.21	gold quality
muscle layer of sigmoid colon	UBERON:0035805	96.21	gold quality
frontal cortex	UBERON:0001870	96.18	gold quality
neocortex	UBERON:0001950	96.18	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	96.17	gold quality
cortical plate	UBERON:0005343	96.12	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-6379	no	331.94
E-MTAB-6524	no	187.32
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

22 targeting CUEDC2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4713-3P	100.00	65.92	505
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-6794-5P	99.76	66.38	1048
HSA-MIR-4716-3P	99.69	66.73	1022
HSA-MIR-892A	99.54	68.16	1141
HSA-MIR-6081	99.48	66.07	1446
HSA-MIR-4318	99.38	66.94	1505
HSA-MIR-4641	99.28	66.64	744
HSA-MIR-6506-5P	99.04	65.66	1386
HSA-MIR-1843	98.97	66.07	838
HSA-MIR-4802-5P	98.97	66.26	833
HSA-MIR-3154	98.94	66.55	1455
HSA-MIR-619-5P	98.57	64.97	1988
HSA-MIR-1199-5P	98.44	66.51	829
HSA-MIR-6751-3P	98.44	66.35	835
HSA-MIR-4303	98.01	68.13	2304
HSA-MIR-5088-5P	97.97	64.28	487
HSA-MIR-4693-5P	97.35	67.02	1234
HSA-MIR-2276-5P	96.27	65.85	937
HSA-MIR-324-5P	95.68	65.20	560
HSA-MIR-6514-5P	95.07	66.02	655

Literature-anchored findings (GeneRIF, showing 21)

• These results identify a key post-translational mechanism that controls progesterone receptor protein levels and for the first time provide an important insight into the function of CUEDC2 in breast cancer proliferation. (PMID:17347654)
• key factor in endocrine resistance in breast cancer (PMID:21572428)
• CUEDC2 is a cell-cycle regulator that promotes spindle checkpoint inactivation and releases APC/C from checkpoint inhibition. CUEDC2 is phosphorylated by Cdk1 during mitosis. (PMID:21743465)
• a new biological activity for CUEDC2 as the regulator of JAK1/STAT3 signaling and the mechanism by which SOCS3 has been linked to suppression of the JAK/STAT pathway (PMID:22084247)
• In response to UV irradiation, CUEDC2 undergoes ERK1/2-dependent phosphorylation and ubiquitin-dependent degradation, leading to APC/C(Cdh1)-mediated cyclin A destruction, cyclin-dependent kinase 2 inactivation, and G1 arrest. (PMID:23776205)
• High CUEDC2 sensitizes chronic myeloid leukemic cells to imatinib treatment. (PMID:24125838)
• CUEDC2 plays a crucial role in modulating macrophage function and is associated with both colitis and colon tumorigenesis. (PMID:24882011)
• Results suggest that decreased expression of CUEDC2 contributes to tumor growth in lung adenocarcinoma, leading to a poor clinical outcome. (PMID:26023733)
• findings show a correlation between the aberrant expression of CUEDC2, and GLUT3 and LDHA in clinical hepatocellular carcinoma samples, further demonstrating a link between CUEDC2 and the Warburg effect during cancer development (PMID:28325773)
• Low CUEDC2 expression is associated with glioma. (PMID:28534933)
• the present study demonstrated that CUEDC2 downregulation prevented DOXinduced cardiotoxicity in H9c2 cells. Therefore, CUEDC2 may be a promising target for the prevention of DOXinduced cardiotoxicity. (PMID:29845245)
• CUEDC2, a novel interacting partner of the SOCS1 protein, plays important roles in the leukaemogenesis of acute myeloid leukaemia (PMID:29991678)
• MicroRNA hsa-miR-324-5p suppresses H5N1 virus replication by targeting the viral PB1 and host CUEDC2. (PMID:30045983)
• High Expression of CUEDC2 is associated with invasion and metastasis in colorectal cancer. (PMID:30651016)
• review of CUEDC2 expression in various tumors, and discussion of several fundamental signaling pathways that are impacted by CUEDC2 [review] (PMID:30844721)
• Kawasaki disease: SOCS2-AS1/miR-324-5p/CUEDC2 axis regulates the progression of human umbilical vein endothelial cells. (PMID:32688371)
• Comparison of ADAM19 and CUEDC2 expression in EHCC and their clinicopathological significance. (PMID:32960074)
• Expression of CUE domain containing 2 protein in serous ovarian cancer tissue: predicting disease-free and overall survival of patients. (PMID:32967504)
• LncRNA BCYRN1 inhibits glioma tumorigenesis by competitively binding with miR-619-5p to regulate CUEDC2 expression and the PTEN/AKT/p21 pathway. (PMID:32978519)
• MicroRNA-324-5p-CUEDC2 Axis Mediates Gain-of-Function Mutant p53-Driven Cancer Stemness. (PMID:34257080)
• Molecular crosstalk between CUEDC2 and ERalpha influences the clinical outcome by regulating mitosis in breast cancer. (PMID:35732909)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	cuedc2	ENSDARG00000039365
mus_musculus	Cuedc2	ENSMUSG00000036748
rattus_norvegicus	Cuedc2	ENSRNOG00000019574
drosophila_melanogaster	CG9636	FBGN0037556

Protein

Protein identifiers

CUE domain-containing protein 2 — Q9H467 (reviewed: Q9H467)

All UniProt accessions (1): Q9H467

UniProt curated annotations — full annotation on UniProt →

Function. Down-regulates ESR1 protein levels through the ubiquitination-proteasome pathway, regardless of the presence of 17 beta-estradiol. Also involved in 17 beta-estradiol-induced ESR1 degradation. Controls PGR protein levels through a similar mechanism.

Subunit / interactions. Interacts with PGR. Interacts with ESR1 in the presence or absence of 17 beta-estradiol.

Subcellular location. Cytoplasm. Nucleus.

Tissue specificity. Significantly up-regulated in breast tumor tissues compared with matched adjacent normal tissues (at protein level). Levels inversely correlate with ESR1 in breast cancers and are lower in low-grade tumors compared to high-grade tumors.

Disease relevance. May predict the clinical outcome of tamoxifen therapy of breast cancer patients. Patients with tumors that highly express CUEDC2 do not respond to tamoxifen treatment as effectively as those with tumors with low expression.

Domain organisation. The CUE domain mediates interaction with PGR and ESR1.

Similarity. Belongs to the CUEDC2 family.

RefSeq proteins (1): NP_076945* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003892	CUE	Domain
IPR039805	CUE_CUED2	Domain

Pfam: PF02845

UniProt features (6 total): chain 1, domain 1, region of interest 1, compositionally biased region 1, modified residue 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H467-F1	72.82	0.29

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 110

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 130 (showing top): GOBP_INFLAMMATORY_RESPONSE, PAL_PRMT5_TARGETS_UP, GOBP_NEGATIVE_REGULATION_OF_PRODUCTION_OF_MOLECULAR_MEDIATOR_OF_IMMUNE_RESPONSE, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, GOBP_NEGATIVE_REGULATION_OF_CYTOKINE_PRODUCTION_INVOLVED_IN_IMMUNE_RESPONSE, GOBP_NEGATIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS, LE_EGR2_TARGETS_UP, GOBP_PRODUCTION_OF_MOLECULAR_MEDIATOR_INVOLVED_IN_INFLAMMATORY_RESPONSE, GOBP_CYTOKINE_PRODUCTION, YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_13, TATA_C, DODD_NASOPHARYNGEAL_CARCINOMA_UP, LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN, GOBP_CYTOKINE_PRODUCTION_INVOLVED_IN_IMMUNE_RESPONSE, GOBP_IMMUNE_EFFECTOR_PROCESS

GO Biological Process (2): negative regulation of macrophage cytokine production (GO:0010936), negative regulation of cytokine production involved in inflammatory response (GO:1900016)

GO Molecular Function (2): ubiquitin binding (GO:0043130), protein binding (GO:0005515)

GO Cellular Component (5): nucleoplasm (GO:0005654), cytosol (GO:0005829), nuclear membrane (GO:0031965), nucleus (GO:0005634), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
negative regulation of cytokine production involved in immune response	1
macrophage cytokine production	1
regulation of macrophage cytokine production	1
negative regulation of cytokine production	1
cytokine production involved in inflammatory response	1
regulation of cytokine production involved in inflammatory response	1
ubiquitin-like protein binding	1
binding	1
nuclear lumen	1
cytoplasm	1
nucleus	1
nuclear envelope	1
organelle membrane	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

608 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CUEDC2	PGR	P06401	776
CUEDC2	CRYBG3	Q68DQ2	575
CUEDC2	ELOC	Q15369	574
CUEDC2	FBXL15	Q9H469	550
CUEDC2	IKBKB	O14920	542
CUEDC2	CHUK	O15111	540
CUEDC2	CUEDC1	Q9NWM3	530
CUEDC2	ESR1	P03372	524
CUEDC2	BUB3	O43684	493
CUEDC2	NR3C1	P04150	477
CUEDC2	PPP1CB	P37140	461
CUEDC2	PPP1CC	P36873	457
CUEDC2	SLC68A1	Q14CX5	455
CUEDC2	TMEM150A	Q86TG1	448
CUEDC2	MYNN	Q9NPC7	436

IntAct

32 interactions, top by confidence:

A	B	Type	Score
PGR	CUEDC2	psi-mi:“MI:0915”(physical association)	0.660
CUEDC2	PGR	psi-mi:“MI:0915”(physical association)	0.660
CUEDC2	PGR	psi-mi:“MI:0403”(colocalization)	0.660
PGR	CUEDC2	psi-mi:“MI:0403”(colocalization)	0.660
TBP	CUEDC2	psi-mi:“MI:0915”(physical association)	0.560
RNF26	NME2P1	psi-mi:“MI:0914”(association)	0.530
CUEDC2	TBP	psi-mi:“MI:0914”(association)	0.530
FZR1	TK1	psi-mi:“MI:0914”(association)	0.530
ESR1	CUEDC2	psi-mi:“MI:0915”(physical association)	0.520
CUEDC2	ESR1	psi-mi:“MI:0915”(physical association)	0.520
CUEDC2	AGTR1	psi-mi:“MI:0915”(physical association)	0.370
CUEDC2	MYCBP2	psi-mi:“MI:0915”(physical association)	0.370
EWSR1	CUEDC2	psi-mi:“MI:0915”(physical association)	0.370
MAPT	MEX3A	psi-mi:“MI:0914”(association)	0.350
NAB2	GRN	psi-mi:“MI:0914”(association)	0.350
hspa1a_hspa1b_human-1	SHTN1	psi-mi:“MI:0914”(association)	0.350
CTLA4	TMEM120B	psi-mi:“MI:0914”(association)	0.350
CAV1	MAP1LC3B2	psi-mi:“MI:0914”(association)	0.350
GTF2A2	S100P	psi-mi:“MI:0914”(association)	0.350
FZR1	CDK1	psi-mi:“MI:0914”(association)	0.350
FZR1	BUB1B	psi-mi:“MI:0914”(association)	0.350
FGFR4	SH3PXD2B	psi-mi:“MI:2364”(proximity)	0.270
TBP	CUEDC2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (76): SOCS3 (Two-hybrid), FZR1 (Affinity Capture-MS), GTF2A1 (Affinity Capture-MS), TBP (Affinity Capture-MS), CUEDC2 (Affinity Capture-MS), CUEDC2 (Two-hybrid), HSPA4 (Affinity Capture-Western), HSPA4 (Affinity Capture-MS), CUEDC2 (Proximity Label-MS), FZR1 (Affinity Capture-MS), CUEDC2 (Affinity Capture-MS), CUEDC2 (Affinity Capture-MS), TBP (Affinity Capture-MS), KHK (Affinity Capture-MS), SOCS1 (Reconstituted Complex)

ESM2 similar proteins: A0JNQ6, A6NC42, A6NGQ2, A6NGR9, A6QP75, A7E3N7, A9X185, E1BDF2, E9PGG2, F6SZT2, P0C7A0, P85965, Q06VW1, Q0ZFW8, Q14DK4, Q3UK37, Q3UV16, Q3ZBN4, Q400G9, Q4VXA5, Q587J8, Q5JSQ8, Q60953, Q60I26, Q60I27, Q6NUI2, Q6ZUX3, Q810I0, Q8BH06, Q8C0R7, Q8IWB1, Q8IWY9, Q8IYX4, Q8K4C2, Q8N6L0, Q8N7F7, Q8NCV1, Q8TE82, Q91WA6, Q95JV3

Diamond homologs: A1L131, Q3ZBN4, Q68F60, Q6NU18, Q6TLH3, Q9CXX9, Q9H467

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

54 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	39
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1283 predictions. Top by Δscore:

Variant	Effect	Δscore
10:102423569:GGGC:G	acceptor_gain	1.0000
10:102423570:GGC:G	acceptor_gain	1.0000
10:102423571:GC:G	acceptor_gain	1.0000
10:102423571:GCC:G	acceptor_loss	1.0000
10:102423572:CC:C	acceptor_gain	1.0000
10:102423573:C:CC	acceptor_gain	1.0000
10:102423573:CTGTC:C	acceptor_loss	1.0000
10:102423647:A:C	donor_gain	1.0000
10:102423652:CTCA:C	donor_loss	1.0000
10:102423653:TCAC:T	donor_loss	1.0000
10:102423654:CA:C	donor_loss	1.0000
10:102423655:A:AC	donor_gain	1.0000
10:102423655:A:AG	donor_loss	1.0000
10:102423655:ACCT:A	donor_gain	1.0000
10:102423656:C:CC	donor_gain	1.0000
10:102423656:CCT:C	donor_gain	1.0000
10:102423656:CCTC:C	donor_gain	1.0000
10:102423658:T:TA	donor_gain	1.0000
10:102423659:C:A	donor_gain	1.0000
10:102423796:A:AC	donor_gain	1.0000
10:102423797:C:CC	donor_gain	1.0000
10:102423797:CTT:C	donor_gain	1.0000
10:102423899:A:T	acceptor_gain	1.0000
10:102423991:GATAC:G	donor_loss	1.0000
10:102423992:ATAC:A	donor_loss	1.0000
10:102423993:TACC:T	donor_loss	1.0000
10:102423994:ACCT:A	donor_loss	1.0000
10:102423995:CCTGG:C	donor_loss	1.0000
10:102424030:T:TA	donor_gain	1.0000
10:102424035:T:A	donor_gain	1.0000

AlphaMissense

1888 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:102423453:C:A	K279N	0.995
10:102423453:C:G	K279N	0.995
10:102423528:G:C	S254R	0.995
10:102423528:G:T	S254R	0.995
10:102423530:T:G	S254R	0.995
10:102423551:A:C	Y247D	0.995
10:102423455:T:C	K279E	0.994
10:102423510:G:C	F260L	0.994
10:102423510:G:T	F260L	0.994
10:102423512:A:G	F260L	0.994
10:102423551:A:G	Y247H	0.993
10:102423553:C:G	R246P	0.993
10:102423807:A:T	I216N	0.993
10:102423440:A:G	Y284H	0.992
10:102423431:G:C	H287D	0.991
10:102423511:A:G	F260S	0.991
10:102423716:A:C	Y220D	0.991
10:102424135:A:T	L152H	0.991
10:102423432:G:C	F286L	0.990
10:102423432:G:T	F286L	0.990
10:102423434:A:G	F286L	0.990
10:102423444:T:A	R282S	0.990
10:102423444:T:G	R282S	0.990
10:102423550:T:G	Y247S	0.990
10:102423807:A:G	I216T	0.990
10:102424122:G:C	F156L	0.990
10:102424122:G:T	F156L	0.990
10:102424124:A:G	F156L	0.990
10:102423521:C:G	G257R	0.989
10:102423521:C:T	G257R	0.989

dbSNP variants (sampled 300 via entrez): RS1000023936 (10:102432501 G>A), RS1000056704 (10:102432142 C>A,T), RS1000082882 (10:102424972 G>A), RS1000102189 (10:102429751 G>A), RS1000473105 (10:102429309 C>T), RS1000621288 (10:102425351 C>T), RS1001017850 (10:102430963 C>T), RS1001048732 (10:102430713 G>A,C), RS1001330523 (10:102423001 G>A), RS1002025059 (10:102429297 G>C), RS1003055229 (10:102427463 C>G), RS1003432504 (10:102427780 T>C), RS1003675322 (10:102424846 C>A), RS1003879684 (10:102428912 C>T), RS1004025722 (10:102432025 A>C,G)

Disease associations

OMIM: gene MIM:614142 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST001942_1	Prostate cancer	5.000000e-10
GCST002639_4	Autism spectrum disorder-related traits	4.000000e-07
GCST005956_50	Waist-to-hip ratio adjusted for BMI	8.000000e-06
GCST005958_15	Waist-to-hip ratio adjusted for BMI (age >50)	4.000000e-06
GCST005962_36	Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test)	6.000000e-07
GCST010002_298	Refractive error	3.000000e-22

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0007788	BMI-adjusted waist-hip ratio
EFO:0008007	age at assessment
EFO:0008343	sex interaction measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

26 total (human), top 26 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	2
triphenyl phosphate	affects expression	1
arsenite	affects binding, increases reaction	1
sodium arsenite	decreases expression	1
cobaltous chloride	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
ICG 001	decreases expression	1
jinfukang	affects cotreatment, increases expression	1
Acetaminophen	decreases expression	1
Air Pollutants	increases abundance, decreases expression	1
Air Pollutants, Occupational	affects expression	1
Caffeine	decreases phosphorylation	1
Cisplatin	affects cotreatment, increases expression	1
Hydralazine	affects cotreatment, increases expression	1
Quercetin	increases expression	1
Selenium	increases expression	1
Smoke	decreases expression	1
Thiram	decreases expression	1
Tunicamycin	decreases expression	1
Urethane	decreases expression	1
Vitamin E	increases expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	increases expression	1
Okadaic Acid	decreases expression	1
Copper Sulfate	decreases expression	1
Particulate Matter	decreases expression, increases abundance	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.